ADAIR CHARLES DAVID has a total of 17 patent applications. Its first patent ever was published in 2002. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and biotechnology are HOUCK JOHN C, CARMOT THERAPEUTICS INC and AMGEN K A INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Australia | 2 | |
#4 | Canada | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Norway | 2 | |
#7 | China | 1 | |
#8 | Hong Kong | 1 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Adair Charles David | 17 |
#2 | Wang Y | 1 |
Publication | Filing date | Title |
---|---|---|
US2010297129A1 | Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia | |
EP2046385A2 | Composition for modulating the expression of cell adhesion molecules | |
WO2007037788A1 | Antibody composition and passive immunization against pregnancy-induced hypertension using antidigoxin antibody (digibind) | |
AU2003254159A1 | Use of digoxin immune Fab for the regulation of sodium/potassium ATPase activity in preeclamptic and eclamptic patients | |
US7402313B2 | Method for controlling preeclampsia and eclampsia |